Cargando…

Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation

BACKGROUND: Given the role of systematic inflammation in cancer progression, lymphocyte-monocyte ratio (LMR) from peripheral blood has been suggested as a biomarker to assess the extent of inflammation in several solid malignancies. However, the role of LMR as a prognostic factor in head and neck ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Brian, Ma, Sung Jun, Khan, Michael, Gill, Jasmin, Iovoli, Austin, Fekrmandi, Fatemeh, Farrugia, Mark K., Wooten, Kimberly, Gupta, Vishal, McSpadden, Ryan, Kuriakose, Moni A., Markiewicz, Michael R., Al-Afif, Ayham, Hicks, Wesley L., Seshadri, Mukund, Ray, Andrew D., Repasky, Elizabeth A., Singh, Anurag K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286492/
https://www.ncbi.nlm.nih.gov/pubmed/37344761
http://dx.doi.org/10.1186/s12885-023-11062-3
_version_ 1785061761962999808
author Yu, Brian
Ma, Sung Jun
Khan, Michael
Gill, Jasmin
Iovoli, Austin
Fekrmandi, Fatemeh
Farrugia, Mark K.
Wooten, Kimberly
Gupta, Vishal
McSpadden, Ryan
Kuriakose, Moni A.
Markiewicz, Michael R.
Al-Afif, Ayham
Hicks, Wesley L.
Seshadri, Mukund
Ray, Andrew D.
Repasky, Elizabeth A.
Singh, Anurag K.
author_facet Yu, Brian
Ma, Sung Jun
Khan, Michael
Gill, Jasmin
Iovoli, Austin
Fekrmandi, Fatemeh
Farrugia, Mark K.
Wooten, Kimberly
Gupta, Vishal
McSpadden, Ryan
Kuriakose, Moni A.
Markiewicz, Michael R.
Al-Afif, Ayham
Hicks, Wesley L.
Seshadri, Mukund
Ray, Andrew D.
Repasky, Elizabeth A.
Singh, Anurag K.
author_sort Yu, Brian
collection PubMed
description BACKGROUND: Given the role of systematic inflammation in cancer progression, lymphocyte-monocyte ratio (LMR) from peripheral blood has been suggested as a biomarker to assess the extent of inflammation in several solid malignancies. However, the role of LMR as a prognostic factor in head and neck cancer was unclear in several meta-analyses, and there is a paucity of literature including patients in North America. We performed an observational cohort study to evaluate the association of LMR with survival outcomes in North American patients with head and neck cancer. METHODS: A single-institution, retrospective database was queried for patients with non-metastatic head and neck cancer who underwent definitive chemoradiation from June 2007 to April 2021 at the Roswell Park Comprehensive Cancer Center. Primary endpoints were overall survival (OS) and cancer-specific survival (CSS). The association of LMR with OS and CSS was examined using nonlinear Cox proportional hazard model using restricted cubic splines (RCS). Cox multivariable analysis (MVA) and Kaplan–Meier method were used to analyze OS and CSS. Pre-radiation LMR was then stratified into high and low based on its median value. Propensity scored matching was used to reduce the selection bias. RESULTS: A total of 476 patients met our criteria. Median follow up was 45.3 months (interquartile range 22.8–74.0). The nonlinear Cox regression model showed that low LMR was associated with worse OS and CSS in a continuous fashion without plateau for both OS and CSS. On Cox MVA, higher LMR as a continuous variable was associated with improved OS (adjusted hazard ratio [aHR] 0,90, 95% confidence interval [CI] 0.82–0.99, p = 0.03) and CSS (aHR 0.83, 95% CI 0.72–0.95, p = 0.009). The median value of LMR was 3.8. After propensity score matching, a total of 186 pairs were matched. Lower LMR than 3.8 remained to be associated with worse OS (HR 1.59, 95% CI 1.12–2.26, p = 0.009) and CSS (HR 1.68, 95% CI 1.08–2.63, p = 0.02). CONCLUSION: Low LMR, both as a continuous variable and dichotomized variable, was associated with worse OS and CSS. Further studies would be warranted to evaluate the role of such prognostic marker to tailor interventions.
format Online
Article
Text
id pubmed-10286492
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102864922023-06-23 Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation Yu, Brian Ma, Sung Jun Khan, Michael Gill, Jasmin Iovoli, Austin Fekrmandi, Fatemeh Farrugia, Mark K. Wooten, Kimberly Gupta, Vishal McSpadden, Ryan Kuriakose, Moni A. Markiewicz, Michael R. Al-Afif, Ayham Hicks, Wesley L. Seshadri, Mukund Ray, Andrew D. Repasky, Elizabeth A. Singh, Anurag K. BMC Cancer Research BACKGROUND: Given the role of systematic inflammation in cancer progression, lymphocyte-monocyte ratio (LMR) from peripheral blood has been suggested as a biomarker to assess the extent of inflammation in several solid malignancies. However, the role of LMR as a prognostic factor in head and neck cancer was unclear in several meta-analyses, and there is a paucity of literature including patients in North America. We performed an observational cohort study to evaluate the association of LMR with survival outcomes in North American patients with head and neck cancer. METHODS: A single-institution, retrospective database was queried for patients with non-metastatic head and neck cancer who underwent definitive chemoradiation from June 2007 to April 2021 at the Roswell Park Comprehensive Cancer Center. Primary endpoints were overall survival (OS) and cancer-specific survival (CSS). The association of LMR with OS and CSS was examined using nonlinear Cox proportional hazard model using restricted cubic splines (RCS). Cox multivariable analysis (MVA) and Kaplan–Meier method were used to analyze OS and CSS. Pre-radiation LMR was then stratified into high and low based on its median value. Propensity scored matching was used to reduce the selection bias. RESULTS: A total of 476 patients met our criteria. Median follow up was 45.3 months (interquartile range 22.8–74.0). The nonlinear Cox regression model showed that low LMR was associated with worse OS and CSS in a continuous fashion without plateau for both OS and CSS. On Cox MVA, higher LMR as a continuous variable was associated with improved OS (adjusted hazard ratio [aHR] 0,90, 95% confidence interval [CI] 0.82–0.99, p = 0.03) and CSS (aHR 0.83, 95% CI 0.72–0.95, p = 0.009). The median value of LMR was 3.8. After propensity score matching, a total of 186 pairs were matched. Lower LMR than 3.8 remained to be associated with worse OS (HR 1.59, 95% CI 1.12–2.26, p = 0.009) and CSS (HR 1.68, 95% CI 1.08–2.63, p = 0.02). CONCLUSION: Low LMR, both as a continuous variable and dichotomized variable, was associated with worse OS and CSS. Further studies would be warranted to evaluate the role of such prognostic marker to tailor interventions. BioMed Central 2023-06-21 /pmc/articles/PMC10286492/ /pubmed/37344761 http://dx.doi.org/10.1186/s12885-023-11062-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yu, Brian
Ma, Sung Jun
Khan, Michael
Gill, Jasmin
Iovoli, Austin
Fekrmandi, Fatemeh
Farrugia, Mark K.
Wooten, Kimberly
Gupta, Vishal
McSpadden, Ryan
Kuriakose, Moni A.
Markiewicz, Michael R.
Al-Afif, Ayham
Hicks, Wesley L.
Seshadri, Mukund
Ray, Andrew D.
Repasky, Elizabeth A.
Singh, Anurag K.
Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation
title Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation
title_full Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation
title_fullStr Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation
title_full_unstemmed Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation
title_short Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation
title_sort association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286492/
https://www.ncbi.nlm.nih.gov/pubmed/37344761
http://dx.doi.org/10.1186/s12885-023-11062-3
work_keys_str_mv AT yubrian associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT masungjun associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT khanmichael associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT gilljasmin associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT iovoliaustin associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT fekrmandifatemeh associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT farrugiamarkk associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT wootenkimberly associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT guptavishal associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT mcspaddenryan associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT kuriakosemonia associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT markiewiczmichaelr associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT alafifayham associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT hickswesleyl associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT seshadrimukund associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT rayandrewd associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT repaskyelizabetha associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation
AT singhanuragk associationofpretreatmentlymphocytemonocyteratiowithsurvivaloutcomeinpatientswithheadandneckcancertreatedwithchemoradiation